製品番号: HY-145994

Obeldesivir

(別名: ATV006)

1 Cited Publications

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

Obeldesivir (ATV006) is a potent, orally active antiviral agent and ester proagents of GS-441524. Obeldesivir inhibits the replication of SARS-CoV-2 and its variants. Obeldesivir can be used for SARS-CoV-2 research.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.53%
CAS 番号: 2647441-36-7
分子式: C₁₆H₁₉N₅O₅
分子量:361.35

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Obeldesivir 構造式

CAS 番号: 2647441-36-7

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (1)
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Cellular Effect

Cell Line	Type	Value	Description	References
Hepatocyte	CC₅₀	>100 μM Compound: 3; GS-5245, ODV	Cytotoxicity against human primary hepatocytes assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human primary hepatocytes assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
HepG2	CC₅₀	71 μM Compound: 3; GS-5245, ODV	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
Huh-7	CC₅₀	>44 μM Compound: 3; GS-5245, ODV	Cytotoxicity against human Huh-7 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
MRC5	CC₅₀	>44 μM Compound: 3; GS-5245, ODV	Cytotoxicity against human MRC5 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human MRC5 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
MT4	CC₅₀	>50 μM Compound: 3; GS-5245, ODV	Cytotoxicity against human MT4 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human MT4 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
PBMC	CC₅₀	>100 μM Compound: 3; GS-5245, ODV	Cytotoxicity against quiescent human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against quiescent human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
PBMC	CC₅₀	>100 μM Compound: 3; GS-5245, ODV	Cytotoxicity against stimulated human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against stimulated human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
PC-3	CC₅₀	>100 μM Compound: 3; GS-5245, ODV	Cytotoxicity against human PC-3 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human PC-3 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]

体外実験

Obeldesivir (0.001-100 μM; 48 h; Vero E6 cells) inhibits the replication of authentic SARS-CoV-2 and its variants of concern. Obeldesivir has an overall >4-fold and >12-fold potency improvement in inhibiting the replication of Delta and Omicron variants, with EC₅₀ values of 0.349 μM and 0.106 μM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Obeldesivir (5-25 mg/kg; p.o. and i.v.; Sprague Dawley rats) has favorable pharmacokinetic profiles in rats with high oral bioavailability (F %) of 81.5% and maximum blood concentration (C_max) of 8.2 μM^[1].
Obeldesivir (250-500 mg/kg; p.o.; daily, for 4 days; hACE2 knock-in and Ad5-hACE2 mice) has antiviral activity and inhibits SARS-CoV-2 replication in mouse models^[1].
Obeldesivir (100-250 mg/kg; p.o.; daily, for 10 days) reduces lung damage and protects K18-hACE2 mice^[1].
Obeldesivir (10-150 mg/kg; p.o.; daily, for 3 days) reduces virus titers and lung damage caused by Delta variant infection in K18-hACE2 mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague Dawley rats^[1]
Dosage:

5 and 25 mg/kg
Administration:

Oral administration (25 mg/kg) and intravenous injection (5 mg/kg)
Result:

1.19

parameters i.v. (5 mg/kg) p.o. (25 mg/kg)

AUC_last (μM·h) 5.6 22.8

T_1/2 (h) 1.5 1.2

T_max (h) 0.5

C_max (μM) 8.7 8.2

F % 81.5

Animal Model:

hACE2 knock-in and Ad5-hACE2 mice^[1]
Dosage:

250 and 500 mg/kg
Administration:

Oral administration; daily, for 4 days
Result:

Inhibited gRNA and sgRNA, which is Biomarkers of coronavirus replication. Reduced the viral load and pathological damage of the lung.

Animal Model:

K18-hACE2 mice^[1]
Dosage:

100 and 250 mg/kg
Administration:

Oral administration; daily, for 10 days
Result:

Reduced viral RNA and increased the survival rate of mice. Reduced evidence of lung pathology and the production of inflammatory cytokines and chemokines in the lung tissues.

Animal Model:

K18-hACE2 mice^[1]
Dosage:

10, 30, 80 and 150 mg/kg
Administration:

Oral administration; daily, for 3 days
Result:

Reduced viral load in a dose-dependent manner and alleviated the symptoms in the lung.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 2647441-36-7
性状 Solid
分子量 361.35
分子式 C₁₆H₁₉N₅O₅
Color White to off-white
SMILES

N#C[C@@]1(C2=CC=C3N2N=CN=C3N)O[C@@H]([C@H]([C@H]1O)O)COC(C(C)C)=O
別名

ATV006
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Microbe

2025 Oct 14.

溶剤 & 溶解度

体外:

DMSO : 250 mg/mL (691.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7674 mL

13.8370 mL

27.6740 mL

5 mM

0.5535 mL

2.7674 mL

5.5348 mL

10 mM

0.2767 mL

1.3837 mL

2.7674 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (285 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Cao L, et, al. The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants. Sci Transl Med. 2022 May 17:eabm7621. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7674 mL	13.8370 mL	27.6740 mL	69.1850 mL
	5 mM	0.5535 mL	2.7674 mL	5.5348 mL	13.8370 mL
	10 mM	0.2767 mL	1.3837 mL	2.7674 mL	6.9185 mL
	15 mM	0.1845 mL	0.9225 mL	1.8449 mL	4.6123 mL
	20 mM	0.1384 mL	0.6918 mL	1.3837 mL	3.4592 mL
	25 mM	0.1107 mL	0.5535 mL	1.1070 mL	2.7674 mL
	30 mM	0.0922 mL	0.4612 mL	0.9225 mL	2.3062 mL
	40 mM	0.0692 mL	0.3459 mL	0.6918 mL	1.7296 mL
	50 mM	0.0553 mL	0.2767 mL	0.5535 mL	1.3837 mL
	60 mM	0.0461 mL	0.2306 mL	0.4612 mL	1.1531 mL
	80 mM	0.0346 mL	0.1730 mL	0.3459 mL	0.8648 mL
	100 mM	0.0277 mL	0.1384 mL	0.2767 mL	0.6918 mL

Keywords

Obeldesivir

1 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Obeldesivir

Anti-Infection Compound Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

MedChemExpress（MCE）の使用を引用している文献 Obeldesivir

生物活性

化学情報

Publications (1)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

parameters	i.v. (5 mg/kg)	p.o. (25 mg/kg)
AUC_last (μM·h)	5.6	22.8
T_1/2 (h)	1.5	1.2
T_max (h)		0.5
C_max (μM)	8.7	8.2
F %		81.5

Obeldesivir

Anti-Infection Compound Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

MedChemExpress（MCE）の使用を引用している文献 Obeldesivir

生物活性

化学情報

Publications (1)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Obeldesivir 関連分類

HY-145994 関連分類